Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FX301
- Development stage
- Phase 1
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Local Injection
01
Overview
FX301 is a Nav1.7 inhibitor that originated as XEN402 (funapide) from Xenon Pharmaceuticals. Flexion Therapeutics acquired the global rights and developed FX301 as an extended-release thermosensitive hydrogel. It is designed to function as a non-opioid peripheral nerve block for the control of post-operative pain. Following the acquisition of Flexion Therapeutics by Pacira BioSciences in November 2021, the drug's development is continued by Pacira, where it is now known as PCRX301.
- Other names
- XEN402XEN-402XEN 402funapidePCRX301PCRX-301PCRX 301
02
Targets
SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on FX301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FX301.